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BACKGROUND. The American Cancer Society, the National Cancer Institute, the North
American Association of Central Cancer Registries (NAACCR), the National Institute
on Aging (NIA), and the Centers for Disease Control and Prevention, including the
National Center for Health Statistics (NCHS) and the National Center for Chronic
Disease Prevention and Health Promotion, collaborated to provide an annual update
on cancer occurrence and trends in the United States. This year’s report contained a
special feature focusing on implications of age and aging on the U.S. cancer burden.
METHODS. For 1995 through 1999, age-specific rates and age-adjusted rates were
calculated for the major cancers using incidence data from the Surveillance, Epide-
miology, and End Results Program, the National Program of Cancer Registries, and the
NAACCR, and mortality data from NCHS. Joinpoint analysis, a model of joined line
segments, was used to examine 1973-1999 trends in incidence and death rates by age
for the four most common cancers. Deaths were classified using the eighth, ninth, and
tenth revisions of the International Classification of Diseases. Age-adjusted incidence
and death rates were standardized to the year 2000 population, which places more
emphasis on older persons, in whom cancer rates are higher.
RESULTS. Across all ages, overall cancer death rates decreased in men and women
from 1993 through 1999, while cancer incidence rates stabilized from 1995 through
2766
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1999. Age-specific trends varied by site, sex, and race. For example, breast cancer
incidence rates increased in women aged 50-64 years, whereas breast cancer death
rates decreased in each age group. However, a major determinant of the future
cancer burden is the demographic phenomenon of the aging and increasing size of
the U.S. population. The total number of cancer cases can be expected to double
by 2050 if current incidence rates remain stable.
CONCLUSIONS. Despite the continuing decrease in cancer death rates and stabili-
zation of cancer incidence rates, the overall growth and aging of the U.S. popula-
tion can be expected to increase the burden of cancer in our nation. Cancer 2002;
94:2766 –92. © 2002 American Cancer Society.
DOI 10.1002/cncr.10593
KEYWORDS: neoplasm, incidence, mortality, aging, race/ethnicity, surveillance,
joinpoint.
The American Cancer Society (ACS), the NationalCancer Institute (NCI), the North American Asso-
ciation of Central Cancer Registries (NAACCR), and
the Centers for Disease Control and Prevention (CDC),
including the National Center for Health Statistics
(NCHS), and the National Center for Chronic Disease
Prevention and Health Promotion, collaborate to pro-
duce an annual report on the current burden of cancer
in the United States. Four years ago, the initial report
documented the first sustained decline in cancer
death rates, a notable reversal in the increases ob-
served since national record keeping was instituted in
the 1930s.1 The second and third reports updated and
confirmed these declines in both cancer incidence
and death rates.2,3 These reports highlighted lung can-
cer and the tobacco epidemic2 and opportunities to
improve the prevention, early detection, and treat-
ment of colorectal cancer.3 The fourth report exam-
ined trends from 1973 through 1998 in the incidence
and death rates for the four most common cancers
(breast, prostate, lung, and colon/rectum), which
make up more than half the cancer burden.4 The
fourth report also featured specific cancers for which
incidence or death rates increased in one or more
population groups during 1992 through 1998.
The current report focuses on cancer rates and
trends in the context of an aging population. As more
of the U.S. population reaches older ages, there are
extensive implications for an increased cancer burden
among older Americans now and in future decades.
The increase in the number of older persons results
from reduced death rates in all age groups, which
yields a greater probability of surviving to an older age
and increased life expectancy (both at birth and at
older ages), and the aging of the 75 million persons
born between 1946 and 1964 (the baby boom era).5–9
The current report examines the impact of age on
current cancer rates and trends and projects the future
cancer burden due to the anticipated growth and ag-
ing of the population through 2050. This report is also
the first in this series to use a revision to the coding
system for cause of death (International Classification
of Diseases [ICD], revision 10), implemented for 1999
deaths, and a change in age-adjustment of cancer
rates to the federally adopted year 2000 population
standard. Also, the National Institute on Aging (NIA)
was invited to participate.
SUBJECTS AND METHODS
Additional data and information on cancer incidence,
mortality, and survival are available from the following
Internet addresses: www.seer.cancer.gov (NCI); www.
naaccr.org/CINAPlus/index.html (NAACCR); www.
cdc.gov/cancer/NPCR (CDC); www.cdc.gov/nchs/about/
major/dvs/mortdata.html (NCHS); and www.cancer.
org (ACS). More detailed information, figures, and
methodology pertaining to this report are available at
the NCI Internet address.
Cancer Cases and Deaths
Information on newly diagnosed cancer cases in the
United States is based on data collected by registries
in the NCI’s Surveillance, Epidemiology, and End Re-
sults (SEER) Program10 and the CDC’s National Pro-
gram of Cancer Registries (NPCR).11 Data from regis-
tries in both programs are evaluated and published
annually by NAACCR.12
Cancer deaths in the United States are reported to
state vital statistics offices and consolidated into a
database by NCHS through the National Vital Statis-
tics System (NVSS).13 That system codes cause of
death according to the version of the ICD in use in the
United States at the time.14 –16 A conversion algorithm
aids comparability between versions of ICD codes,
which are categorized according to SEER site groups.10
For the long-term trend analyses, SEER incidence
(original areas covering 10% of the U.S. population)
and U.S. death data from NCHS for 1973 through 1999
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were used. For the age-specific analyses of current
cancer occurrence, the SEER and NPCR incidence
data reported by NAACCR were used; these data are
from 28 registries that meet NAACCR criteria for high-
est quality data for 1995 through 1999.12 Approxi-
mately 55% of the U.S. population is included in the
NAACCR combined cancer incidence rates. For vari-
ous racial and ethnic populations, estimates of recent
(1995-1999) rates and the proportion of cases and
deaths contributed by each cancer were based on
incidence data from SEER (1992 expansion areas cov-
ering 14% of the U.S. population) and U.S. mortality
data. All information on primary site and histology for
incidence was converted to the International Classifi-
cation of Diseases for Oncology, second edition
(ICDO-2),17 and categorized according to SEER site
groups.10
Methodologic Changes
Two methodologic changes were made for the current
report that affect the comparability of data with that of
previous years. One is the change in the coding and
classification of causes of death reported on death
certificates and the other, more influential, is the
change to a contemporary population age distribution
used in age standardization for both incidence and
death rates.
Changes in coding of mortality data effective with 1999
deaths
Effective with deaths in 1999, in the United States
causes of death were coded and classified according to
the tenth revision of the World Health Organization’s
ICD (ICD-10),16 rather than the ninth revision (ICD-
9)15 used from 1979-1998. Among the many changes in
ICD-10 were increases in classification detail, the shift
to an alphanumeric classification system, and a num-
ber of changes in the coding rules by which a single
cause of death is selected from among the multiple
causes reported by physicians as causing or contrib-
uting to the death. The change from ICD-9 to ICD-10
caused discontinuities in trends for many causes of
death, including cancer. The nature and extent of
these discontinuities are described in a recent re-
port.18 The extent of these discontinuities is measured
by comparability studies in which death records are
double coded by the two revisions and results com-
pared. Overall, approximately 0.7% more deaths are
assigned to cancer under ICD-10. For certain cancers,
however, discontinuities are greater or lesser, in part
due to the allowed use of categories for persons who
died with more than one cancer or died from meta-
static disease.
Changes in population standard effective with 1999 cases
and deaths
Also affecting reporting incidence and mortality data
for 1999, the standard population used to age-adjust
cancer incidence and death rates was changed to the
year 2000 U.S. standard million population. All age-
adjusted rates and age-specific rates covering more
than a five year age group presented in the current
report used the new year 2000 population standard.
The change to the year 2000, which recently was
adopted uniformly by federal health agencies, has
consequences for the levels of cancer rates, and, in
some cases, for comparisons over time and among
groups.19 Earlier reports on death rates from the
NCHS were based on the 1940 standard population,20
whereas most earlier reports on cancer incidence and
death rates were based on a 1970 standard popula-
tion.21 Thus, age-adjusted rates and trends in the cur-
rent report cannot be compared with previously pub-
lished reports. Further, rates adjusted to the 2000
standard produce cancer incidence and death rates
20% to 50% higher than rates published to the 1970
standard. More detailed information on the effect of
age-adjustment can be found on the following Internet
addresses: www.cdc.gov/nchs/data/ IW134Pfct.pdf
(NCHS); and www.naaccr.org/Training/html/2000pop/
2000pop.html (NAACCR).
Cancer Incidence and Death Rates
The U.S. Census Bureau provided annual county res-
ident population estimates that were used in the com-
putation of incidence and death rates. Population data
for Hawaii were adjusted slightly for an undercount of
Asian/Pacific Islanders.
All rates were expressed per 100,000 population
and age-adjusted by the direct method to the new year
2000 standard. For the current report, all calculated
rates had at least 25 cases or deaths in the population
of interest. The term “all sites” refers to all invasive
cancer sites combined (excluding basal and squamous
cell carcinoma of the skin, and including in situ blad-
der carcinoma), as well as other sites not shown in the
tables or figures.
This year’s report features information by age-
specific groups ( 20 years old, 20 to 49 years,  50
years, 50 to 64 years, 65 to 74 years, and 75 years and
older) based on SEER incidence and survival rates,
NAACCR reported incidence rates, or the U.S. death
rates in either sex among the total, white, or black
population. The interval of 1995 through 1999 was
chosen for cancer-specific incidence and death rates
to represent the broadest cross-section of the current
burden and to improve the precision of rates esti-
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mated and data interpretability for all populations in
the analyses (Hispanic, black, American Indian/Alaska
Native [AI/AN], Asian/Pacific Islander [API], and
white). Hispanic ethnicity is not a mutually exclusive
group from the four race categories. The interval 1973
through 1999 was used for analysis of long-term
trends as it was the longest period for which compa-
rable SEER incidence data were available. Availability
and accuracy of information on race and ethnicity
limit estimation of long-term trends for some popula-
tions.
Projections of future cancer cases for 2000
through 2050 were calculated using 1999 age-specific
NAACCR reported incidence rates applied to national
population projections reported by the U.S. Census
Bureau.6,7 These projections assume that cancer inci-
dence rates do not change during the 50-year period.
Survival and Cancer Prevalence
Survival is estimated from SEER data (persons diag-
nosed in 1990-1998 and followed through 1999) using
standard methods of following persons with cancer
until they die or were known to be alive at a point in
time. Standard life table procedures were used to cal-
culate observed survival rates, the proportion of can-
cer patients surviving for a specified time after diag-
nosis.22 Relative survival is defined as the ratio of
observed survival to expected survival in a comparable
group of cancer-free individuals. This estimate pre-
dicts the effect of the cancer alone on the patient
cohort while ignoring deaths not associated with the
cancer.22
Cancer prevalence is the number of cancer survi-
vors currently alive. For the current report, prevalence
was estimated from SEER incidence and followup data
from 1978 through 1997. The numbers were projected
to the U.S. population on January 1, 1998, and repre-
sent estimated complete prevalence.10 While SEER
does not represent a random sample of the U.S. pop-
ulation, it is more representative than a single registry.
Moreover, the use of multiple SEER registries from
around the country allows calculation of prevalence
statistics; prevalence statistics can be calculated for
different groups characterized by race/ethnicity, age
at diagnosis, and length of survivorship.23
Statistical Analyses
Long-term trends are conveniently described by join-
point analysis (JPA), a statistical model of joined lines
(straight lines on a log scale). This analysis chooses a
model of line segments such that each are joined at
points called a “joinpoint.” Each joinpoint denotes a
statistically significant change in trend.24 For JPA, the
overall significance level was set to P  0.05, and
allowed for a maximum of three joinpoints and four
line segments allowed. An annual percent change
(APC) was used to describe the trend for each line
segment with statistical significance assessed using a
two-sided P  0.05.
RESULTS
Relationship of Age to Cancer Incidence and Mortality
Cancer incidence and death rates increased with age
(Fig. 1). Rates for 1995–1999 were generally higher for
men than for women, except for persons below the
age of 50, where women had higher cancer incidence
and death rates. Cancer rates for persons aged 50-64
years were 7- to 16-fold higher than rates for younger
persons, and rates for persons aged 65-74 years were
2- to 3-fold higher than rates for persons aged 50-64
years. The incidence and death rates for persons aged
75 years and older were higher still, with death rates
two-fold higher than rates for persons aged 65-74
years.
The decrease in age-adjusted death rates from
1990 through 1999 did not offset the increase in the
population size or the absolute number of cancer
deaths (Fig. 2). During the period 1990 through 1999,
the U.S. age-adjusted death rates (top panel) de-
creased by almost 6%. The decrease was larger for
persons younger than age 65 years than in persons
aged 65 years and older (data not shown). The U.S.
population (second panel) increased by almost 10%
(24 million), with a slightly larger percentage increase
of persons aged 65 years and older. As a consequence
of the aging population, the total number of cancer
deaths (third panel) during the 1990s increased about
9% (44,500 deaths), due to the increase in the number
of cancer deaths among persons aged 65 years and
older.
Long-Term Trends in Incidence by Age, Sex, and Race
(White, Black)
While the JPA describes long-term trends, the focus
for the presentation of results is on the most recent
line segment from the analysis; thus, the years cov-
ered will vary for different cancers. During the pe-
riod 1995 through 1999, the overall cancer incidence
rate was stable; however, for certain site, age, sex,
and race groups, rates increased, decreased, or re-
mained stable (Table 1). For example, males had
stable overall cancer incidence rates and females
had increasing rates.
For men under 50 years, cancer incidence rates
decreased, while such rates were stable for men aged
50 years and older. Even among men less than 50 years
of age, not all incidence rates decreased: prostate can-
cer increased, while lung and colorectal cancer de-
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creased. Similarly, for men aged 50 years and older,
the stable rate overall masked decreases in lung can-
cer for each of the older age groups, a decrease in
colorectal cancer in men aged 50-64 and 65-74 years,
and an increase in prostate cancer for men aged 50-64
years. Overall, cancer incidence rates declined in black
men during 1992-1999 and stabilized in white men for
the 1995-1999 time period. Rates decreased in both
black and white men under age 50 and in black men
aged 65-74 years.
For women, overall cancer incidence rates in-
creased from 1987 to 1999, due to increased rates
among women aged 50-64 and 65-74 years. In partic-
ular, breast cancer rates increased for black and white
women aged 50-64 years, and lung cancer rates in-
creased for women 65-74 years. The trends also varied
by cancer type. Incidence rates decreased for lung
cancer but increased for colorectal cancer among
women under age 50 years, while colorectal cancer
incidence rates decreased for women aged 75 years
and older. Race differences were evident among
women in the same age groups. Colorectal cancer
incidence rates increased for white women under 50
years but not for black women, and decreased for
white women aged 50-64 years but increased for black
women in this age group.
Long-Term Trends in Cancer Death Rates by Age, Sex,
and Race (White, Black)
The U.S. death rate from all cancers combined de-
creased an average of more than 1% per year from
1993 to 1999 (Table 2). Total cancer mortality de-
creased during the most recent time interval in black
and white men for each age group and in women for
each age group except those aged 75 years and older.
For women aged 75 years and older, rates were stable
for white women and increased for black women. The
continuing decline in death rates involved all of the
four most common cancer sites. Lung cancer mortal-
ity decreased during the 1990s in men for each age
group and in women under age 65 years. Prostate
cancer death rates decreased for each age group in
black men and in white men, except for white men
aged less than 50 years. Breast cancer mortality de-
creased for each age group in white women and in
black women less than 65 years of age, with increases
for black women aged 75 years and older. While most
age groups and cancers have shown declines, reduc-
tions for women were limited to ages younger than 75
years for all sites combined, and to ages below 65
years for death due to lung cancer.
The decline in cancer death rates during the
1990s reflects longer term mortality trends in which
FIGURE 1. Average annual cancer incidence and death rates for all cancers combined by gender and age, 1995-1999. Incidence: Surveillance, Epidemiology and
End Results Program and the National Program of Cancer Registries areas reported by the North American Association of Central Cancer Registries as meeting high
data quality standards. The areas cover approximately 55% of the U.S. population: California (Los Angeles and Greater Bay area), Colorado, Connecticut, Delaware,
Georgia (Atlanta area), Hawaii, Idaho, Illinois, Iowa, Kentucky, Louisiana, Michigan (Detroit area), Minnesota, Nebraska, New Jersey, New Mexico, New York, North
Carolina, Pennsylvania, Rhode Island, Utah, Washington (Seattle area), West Virginia, Wisconsin, and Wyoming. Death data are from the National Vital Statistics
System of the National Center for Health Statistics; the data cover the entire U.S. population. Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard
population.
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the downturn in rates began earlier and was larger
proportionately at younger than at older ages (Table
2). By the mid-1970s, the death rate from all cancers
combined was decreasing by about 4% per year for
persons  20 years of age and about 2% per year for
persons aged 20-49 years, although the rate of in-
crease was less than 1% per year in persons aged 50
and older. By the 1990s, age- and race-specific can-
cer death rates had stopped increasing and had
begun to decrease among white and black persons
of all ages, except women aged 75 years and older.
Despite differences in the magnitude and timing of
the long-term trends in mortality across the four
most common cancer sites, the death rates de-
creased during the 1990s in most age and race sub-
groups, with the exception of older women, partic-
ularly lung cancer deaths.
Top 10 Cancer Incidence Sites by Age and Sex,
1995-1999
The 10 most frequently occurring cancers within each
of five age groups were ranked by the frequency of
cases for both sexes combined (Table 3). The most
frequent cancers among persons younger than 20
years of age were different from those occurring in
older age groups, with leukemia and cancers of the
brain and other nervous system accounting for more
than 40% of their cancers. The difference in cancer
incidence rates among young men and women was
small.
Among persons aged 20-49 years, breast cancer
incidence was substantially higher than any other can-
cer, representing about one-fourth of all cancers diag-
nosed in this age group. Melanoma, colorectal cancer,
and lung cancer ranked high in frequency for this age
group, with incidence rates for these three cancers in
men and women being similar, in contrast to sex-
specific rates reported for older aged groups. In addi-
tion, non-Hodgkin lymphoma, oral cavity/pharynx,
and testis cancer were common in men, while cancer
of the cervix, ovary, and thyroid were common in
women. In contrast to other age groups, age-adjusted
cancer incidence rates for all sites combined among
persons aged 20-49 years were much higher for
women than for men.
Beginning with the 50-64 year-old age category,
breast, prostate, lung, and colorectal cancers emerged
as the most frequently occurring cancers, an observa-
tion that persisted for all older age groups, although
the rank order changed among the three oldest age
groups. Breast cancer occurred most frequently
among persons aged 50-64 years, with nearly all cases
occurring in women, while prostate cancer ranked
first among persons aged 65-74 years, and colorectal
cancer was first among persons aged 75 years and
older. Lung cancer ranked second among persons
aged 65-74 years and 75 years and older. The magni-
tude of the rates for lung and colorectal cancers varied
substantially by sex in the older age categories.
Although the median age for the incidence of all
cancers combined was 68 years, the range of the me-
dian age at diagnosis varied widely for specific cancers
(Fig. 3). For the four most common cancers (breast,
prostate, lung, and colorectal), the percentage of per-
sons aged 65 years and older ranged from nearly 50%
to more than 70%. Gallbladder cancer had the highest
median age at 73 years, with 76% of the cancers oc-
curring in persons aged 65 years and older, and 40% or
more of cancers of the gallbladder, colon/rectum,
pancreas, stomach, urinary bladder, and pleura were
diagnosed in persons aged 75 years and older. On the
FIGURE 2. Trends in cancer death rates, frequencies and trends in popu-
lation, United States, 1990-1999. Rates are per 100,000 and are age-adjusted
to the 2000 U.S. standard population. Death data are from the National Vital
Statistics System of the National Center for Health Statistics; the data cover the
entire U.S. population. While the rate is 202.8 for 1999 based on the Interna-
tional Classification of Diseases (ICD), revision 10, definitions, the rate would
have been lower, approximately 201.4, if the cancer definitions and rules from
ICD revision 9 were used based on a comparability study.
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TABLE 1
Cancer Incidence Trends by Joinpoint Analysesa for 1973 through 1999 for the Most Common Cancers by Race, Sex,
and Age, SEER,b 1973–1999
Incidence
Line segment 1 Line segment 2 Line segment 3 Line segment 4
Year APCc Year APCc Year APCc Year APCc
All sites All races, both sexes All ages 1973–83 0.9d 1983–92 1.8d 1992–95 1.9 1995–99 0.2
 20 1973–91 1.0d 1991–99 0.2
20–49 1973–80 0.6d 1980–90 1.5d 1990–99 0.7d
 50 1973–80 0.5d 1980–90 1.5d 1990–99 0.7d
50–64 1973–99 0.9d
65–74 1973–89 1.7d 1989–92 4.8d 1992–95 3.3d 1995–99 0.2
75 1973–92 1.5d 1992–95 3.3 1995–99 0.2
All races, males All ages 1973–89 1.4d 1989–92 5.0d 1992–95 4.9d 1995–99 0.3
 20 1973–97 0.8d 1997–99 4.7
20–49 1973–82 0.5d 1982–87 3.5d 1987–92 1.2d 1992–99 2.4d
 50 1973–82 0.4d 1982–86 3.8d 1986–92 1.3d 1992–99 2.2d
50–64 1973–85 1.3d 1985–89 0.2 1989–92 4.6d 1992–99 0.1
65–74 1973–89 1.6d 1989–92 8.2d 1992–95 5.5d 1995–99 0.2
75 1973–89 1.3d 1989–92 4.0 1992–95 7.8d 1995–99 0.1
All races, females All ages 1973–80 0.2 1980–87 1.6d 1987–99 0.3d
 20 1973–99 0.7d
20–49 1973–80 1.2d 1980–86 1.2d 1986–99 0.2
 50 1973–80 1.1d 1980–86 1.2d 1986–99 0.2
50–64 1973–75 3.5 1975–78 2.2 1978–99 0.7d
65–74 1973–78 0.6 1978–87 2.4d 1987–99 0.3d
75 1973–89 1.5d 1989–99 0.1
White, both sexes All ages 1973–83 1.0d 1983–92 1.9d 1992–95 2.1 1995–99 0.2
 20 1973–99 0.7d
20–49 1973–80 0.5 1980–89 1.9d 1989–99 0.7d
 50 1973–80 0.4 1980–89 1.9d 1989–99 0.7d
50–64 1973–82 0.4 1982–92 1.3d 1992–99 0.5
65–74 1973–89 1.8d 1989–92 4.8d 1992–95 3.5d 1995–99 0.3
75 1973–92 1.5d 1992–95 3.5 1995–99 0.2
White, males All ages 1973–89 1.4d 1989–92 4.9d 1992–95 5.3d 1995–99 0.2
 20 1973–99 0.6d
20–49 1973–83 0.7d 1983–86 5.8d 1986–92 1.1d 1992–99 2.7d
 50 1973–82 0.6d 1982–86 4.2d 1986–91 1.7d 1991–99 2.3d
50–64 1973–89 1.1d 1989–92 3.9d 1992–99 0.1
65–74 1973–88 1.5d 1988–92 6.6d 1992–95 5.6d 1995–99 0.2
75 1973–89 1.4d 1989–92 3.7 1992–95 8.0d 1995–99 0.2
White, females All ages 1973–80 0.3 1980–87 1.7d 1987–99 0.3d
 20 1973–99 0.8d
20–49 1973–80 0.9d 1980–90 1.1d 1990–93 1.4 1993–99 0.7d
 50 1973–80 0.8d 1980–87 1.2d 1987–99 0.1
50–64 1973–75 3.7 1975–78 2.3 1978–99 0.7d
65–74 1973–78 0.8 1978–87 2.5d 1987–99 0.3d
75 1973–89 1.6d 1989–99 0.1
Black, both sexes All ages 1973–84 1.5d 1984–89 0.5 1989–92 4.4d 1992–99 1.4d
 20 1973–99 0.6d
20–49 1973–82 0.9 1982–94 1.1d 1994–99 2.1d
 50 1973–82 0.8 1982–94 1.1d 1994–99 2.1d
50–64 1973–83 2.3d 1983–90 0.1 1990–93 4.5 1993–99 0.5
65–74 1973–89 1.8d 1989–92 6.2 1992–99 2.4d
75 1973–92 1.4d 1992–99 1.3d
Black, males All ages 1973–81 2.6d 1981–89 0.6 1989–92 6.7d 1992–99 2.7d
 20 1973–99 1.0d
20–49 1973–85 0.3 1985–95 1.9d 1995–99 5.1d
 50 1973–86 0.1 1986–89 4.8 1989–95 0.7 1995–99 4.1d
50–64 1973–82 3.2d 1982–89 1.0 1989–93 6.4d 1993–99 1.0
(continued)
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TABLE 1
(continued)
Incidence
Line segment 1 Line segment 2 Line segment 3 Line segment 4
Year APCc Year APCc Year APCc Year APCc
65–74 1973–89 1.8d 1989–92 9.5 1992–99 4.1d
75 1973–89 1.6d 1989–92 5.4 1992–95 7.9 1995–99 0.6
Black, females All ages 1973–91 1.1d 1991–99 0.1
 20 1973–99 0.3
20–49 1973–99 0.1
 50 1973–99 0.1
50–64 1973–86 1.7d 1986–99 0.3
65–74 1973–90 2.1d 1990–99 0.0
75 1973–99 1.0d
Lung and bronchus All races, both sexes All ages 1973–81 3.0d 1981–91 1.1d 1991–99 0.9d
 50 1973–77 3.5 1977–99 2.8d
50–64 1973–79 3.4d 1979–88 0.9d 1988–99 2.5d
65–74 1973–81 3.8d 1981–92 1.5d 1992–99 0.6d
75 1973–91 3.0d 1991–99 0.9d
All races, males All ages 1973–80 2.2d 1980–91 0.2 1991–99 2.2d
 50 1973–77 0.7 1977–88 2.7d 1988–99 4.1d
50–64 1973–78 2.4d 1978–87 0.1 1987–99 3.2d
65–74 1973–81 2.1d 1981–92 0.1 1992–99 1.9d
75 1973–76 6.6d 1976–91 1.1d 1991–99 1.3d
All races, females All ages 1973–81 6.3d 1981–91 3.4d 1991–99 0.5
 50 1973–76 10.2d 1976–99 2.0d
50–64 1973–81 6.2d 1981–90 2.2d 1990–99 1.7d
65–74 1973–82 8.8d 1982–91 4.5d 1991–99 1.2d
75 1973–89 7.0d 1989–97 4.2d 1997–99 0.8
White, both sexes All ages 1973–81 3.0d 1981–91 1.2d 1991–99 0.9d
 50 1973–78 2.3 1978–99 3.1d
50–64 1973–78 3.7d 1978–88 1.1d 1988–99 2.4d
65–74 1973–81 3.8d 1981–92 1.6d 1992–99 0.5
75 1973–91 3.2d 1991–99 0.8d
White, males All ages 1973–80 2.1d 1980–91 0.2 1991–99 2.3d
 50 1973–85 2.0d 1985–99 4.3d
50–64 1973–78 2.1d 1978–88 0.2 1988–99 3.5d
65–74 1973–81 1.8d 1981–92 0.1 1992–99 1.9d
75 1973–77 5.4d 1977–91 1.1d 1991–99 1.6d
White, females All ages 1973–76 10.4d 1976–88 4.8d 1988–99 1.2d
 50 1973–78 5.3d 1978–99 2.3d
50–64 1973–82 6.0d 1982–91 1.7d 1991–99 1.8d
65–74 1973–81 9.4d 1981–88 5.7d 1988–99 2.1d
75 1973–89 7.5d 1989–97 4.3d 1997–99 1.1
Black, both sexes All ages 1973–84 3.2d 1984–99 0.5d
 50 1973–99 2.2d
50–64 1973–84 3.8d 1984–99 2.2d
65–74 1973–92 2.6d 1992–99 2.7d
75 1973–99 2.5d
Black, males All ages 1973–84 2.9d 1984–99 1.6d
 50 1973–99 2.6d
50–64 1973–84 2.9d 1984–99 2.9d
65–74 1973–85 3.2d 1985–99 1.7d
75 1973–99 1.3d
Black, females All ages 1973–90 4.4d 1990–99 0.2
 50 1973–99 1.4d
50–64 1973–85 6.9d 1985–99 0.9
65–74 1973–91 7.3d 1991–99 0.4
75 1973–99 5.1d
(continued)
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TABLE 1
(continued)
Incidence
Line segment 1 Line segment 2 Line segment 3 Line segment 4
Year APCc Year APCc Year APCc Year APCc
Colon and rectum All races, both sexes All ages 1973–85 0.9d 1985–95 1.8d 1995–99 0.3
 50 1973–94 1.0d 1994–99 2.6d
50–64 1973–85 0.7d 1985–99 1.3d
65–74 1973–85 0.7d 1985–96 1.7d 1996–99 0.6
75 1973–80 2.2d 1980–88 0.1 1988–95 2.5d 1995–99 0.2
All races, males All ages 1973–86 1.1d 1986–95 2.1d 1995–99 0.1
 50 1973–99 0.3d
50–64 1973–85 1.2d 1985–99 1.1d
65–74 1973–86 0.9d 1986–99 1.7d
75 1973–79 2.5d 1979–88 0.5 1988–95 3.2d 1995–99 0.1
All races, females All ages 1973–84 0.6d 1984–95 1.7d 1995–99 0.7
 50 1973–96 1.4d 1996–99 9.2d
50–64 1973–81 0.6 1981–99 1.3d
65–74 1973–85 0.3 1985–93 2.0d 1993–99 0.2
75 1973–81 2.4d 1981–99 1.2d
White, both sexes All ages 1973–85 0.9d 1985–95 1.9d 1995–99 0.3
 50 1973–95 1.3d 1995–99 4.5d
50–64 1973–85 0.6d 1985–99 1.5d
65–74 1973–85 0.6d 1985–96 1.7d 1996–99 0.6
75 1973–84 1.5d 1984–99 1.6d
White, males All ages 1973–86 1.1d 1986–95 2.3d 1995–99 0.0
 50 1973–99 0.5d
50–64 1973–85 1.1d 1985–99 1.3d
65–74 1973–85 1.0d 1985–99 1.7d
75 1973–87 1.3d 1987–95 3.2d 1995–99 0.1
White, females All ages 1973–84 0.7d 1984–94 2.0d 1994–99 0.2
 50 1973–95 1.9d 1995–99 6.6d
50–64 1973–81 0.7 1981–99 1.6d
65–74 1973–85 0.4 1985–88 3.9 1988–99 0.7d
75 1973–83 1.7d 1983–99 1.5d
Black, both sexes All ages 1973–80 3.6d 1980–99 0.3
 50 1973–99 0.1
50–64 1973–78 5.3d 1978–99 0.4
65–74 1973–89 1.8d 1989–99 1.8d
75 1973–78 6.8d 1978–99 0.6d
Black, males All ages 1973–80 4.9d 1980–99 0.3
 50 1973–97 0.9d 1997–99 16.0
50–64 1973–99 1.0d
65–74 1973–92 1.7d 1992–99 4.1d
75 1973–77 14.8 1977–99 0.6
Black, females All ages 1973–80 2.7d 1980–99 0.3
 50 1973–99 0.2
50–64 1973–99 0.6d
65–74 1973–83 3.1d 1983–99 0.6
75 1973–99 0.2
Female breast All races All ages 1973–80 0.6 1980–87 3.7d 1987–99 0.5d
 50 1973–80 1.5 1980–86 2.9d 1986–99 0.3
50–64 1973–80 1.2 1980–85 4.1d 1985–99 1.6d
65–74 1973–78 1.2 1978–87 4.6d 1987–99 0.4
75 1973–82 0.8 1982–87 5.2d 1987–99 0.0
White All ages 1973–80 0.5 1980–87 3.8d 1987–99 0.4
 50 1973–80 1.4d 1980–86 2.9d 1986–99 0.4
50–64 1973–80 1.1 1980–85 4.4d 1985–99 1.5d
65–74 1973–78 1.0 1978–87 4.7d 1987–99 0.3
75 1973–82 0.8 1982–87 5.4d 1987–99 0.0
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other hand, testicular cancer had the lowest median
age at 34 years, with slightly more than 90% of the
cancers diagnosed before age 50. Also, 70% of persons
with non-Hodgkin lymphoma and more than half of
the persons with cancers of the bones and joints,
cervix, thyroid, and Hodgkin lymphoma were under
the age of 50 years.
Top 10 Cancer Mortality Sites by Age and Sex,
1995-1999
Lung cancer was the leading cause of cancer deaths,
accounting for almost one-third of deaths in men and
about one-fourth of deaths in women (Table 4). Colo-
rectal cancer was the second leading cause of cancer
death overall, accounting for about 10% of deaths,
with breast and prostate cancer deaths together rep-
resenting another 14%. The percentage distribution
and rank order varies when calculated only for men or
for women. These four cancers account for more than
half of all cancer deaths. Six other cancers (pancreas,
non-Hodgkin lymphoma, leukemia, ovary, stomach,
brain and other nervous system) account for almost
one-fourth of cancer deaths, with many other types
contributing to the remaining 27%.
More than 30% of cancer deaths among persons
less than 20 years of age were due to leukemia, and
one-fourth were due to brain and other nervous sys-
tem cancers. A number of other types of cancers ac-
count for the remaining cancer deaths in young per-
sons.
Cancer death rates among persons aged 20 to 49
years were more than 10-fold higher than rates in
children and teenagers, with cancer of the lung and
bronchus emerging as a leading cause of death, par-
ticularly among men, and breast cancer causing 30%
of the cancer deaths in women. Colorectal cancer,
brain and other nervous system cancers, as well as
non-Hodgkin lymphoma and leukemia, accounted for
one-fourth of cancer deaths in this age group. Overall
cancer death rates were slightly higher in women than
in men.
Lung cancer was responsible for about one-third
of all deaths for persons aged 50-64 years and 65-74
years. Colorectal cancer accounted for about 8-10% of
TABLE 1
(continued)
Incidence
Line segment 1 Line segment 2 Line segment 3 Line segment 4
Year APCc Year APCc Year APCc Year APCc
Black All ages 1973–79 0.7 1979–86 3.9d 1986–99 0.9d
 50 1973–91 1.4d 1991–99 1.1
50–64 1973–99 2.1d
65–74 1973–99 2.2d
75 1973–99 1.7d
Prostate All races All ages 1973–88 2.7d 1988–92 16.2d 1992–95 11.7d 1995–99 1.4
 50 1973–90 3.0d 1990–93 33.6d 1993–99 10.9d
50–64 1973–85 2.9d 1985–89 7.3d 1989–92 26.4d 1992–99 2.3d
65–74 1973–88 3.7d 1988–92 20.1d 1992–95 11.2d 1995–99 0.6
75 1973–88 2.0d 1988–92 11.3d 1992–95 18.7d 1995–99 0.1
White All ages 1973–88 2.8d 1988–92 16.1d 1992–95 12.8d 1995–99 1.6
 50 1973–89 3.5d 1989–93 24.5d 1993–99 9.7d
50–64 1973–88 3.7d 1988–92 23.5d 1992–99 2.0d
65–74 1973–88 4.0d 1988–92 20.0d 1992–95 12.3d 1995–99 0.9
75 1973–88 2.1d 1988–92 11.0d 1992–95 19.6d 1995–99 0.1
Black All ages 1973–89 2.1d 1989–92 20.6d 1992–96 5.7d 1996–99 0.1
 50 e e
50–64 1973–89 2.2d 1989–93 26.2d 1993–99 1.4
65–74 1973–89 2.4d 1989–92 24.7d 1992–99 5.0d
75 1973–89 1.9d 1989–92 14.3d 1992–95 16.3d 1995–99 1.0
a Joinpoint analysis of trends allowed for up to three joinpoints based on rates per 100,000 that were age-adjusted to the 2000 U.S. standard population.
b From SEER registries covering 10% of the U.S. population: metropolitan areas of San Francisco, Detroit, Atlanta, and Seattle-Puget Sound; and states of Connecticut, Hawaii, Iowa, Utah, and New Mexico.
c The APC is the Annual Percent Change based on rates age-adjusted to the 2000 U.S. standard population using the joinpoint regression program.
d The APC is statistically significantly different from zero (two-sided P  .05).
e Joinpoint results are not shown if less than 10 cases in any year.
SEER: Surveillance, Epidemiology and End Results program.
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TABLE 2
Cancer Death Trends by Joinpoint Analysesa for the Most Common Cancers by Race, Sex, and Age, United States,b 1973–1999
Mortality
Line segment 1 Line segment 2 Line segment 3 Line segment 4
Year APCc Year APCc Year APCc Year APCc
All sites All races, both sexes All ages 1973–85 0.5d 1985–93 0.2d 1993–99 1.1d
 20 1973–78 4.2d 1978–82 1.0 1982–85 4.9 1985–99 2.2d
20–49 1973–76 2.1d 1976–91 1.2d 1991–99 1.9d
 50 1973–76 2.2d 1976–91 1.3d 1991–99 1.9d
50–64 1973–85 0.3d 1985–91 0.4d 1991–99 1.9d
65–74 1973–86 0.9d 1986–93 0.3d 1993–99 1.0d
75 1973–93 0.9d 1993–99 0.3d
All races, males All ages 1973–80 0.9d 1980–92 0.3d 1992–99 1.5d
 20 1973–99 2.8d
20–49 1973–91 1.3d 1991–99 1.8d
 50 1973–92 1.4d 1992–99 1.9d
50–64 1973–78 0.6d 1978–90 0.1 1990–99 2.1d
65–74 1973–80 0.9d 1980–90 0.3d 1990–94 0.6d 1994–99 1.4d
75 1973–79 1.6d 1979–92 0.9d 1992–99 1.2d
All races, females All ages 1973–92 0.5d 1992–99 0.6d
 20 1973–76 5.5d 1976–99 2.3d
20–49 1973–79 1.9d 1979–91 1.0d 1991–99 2.1d
 50 1973–79 2.0d 1979–91 1.1d 1991–99 2.1d
50–64 1973–87 0.3d 1987–95 0.9d 1995–99 2.3d
65–74 1973–75 0.3 1975–86 1.5d 1986–94 0.7d 1994–99 0.8d
75 1973–87 0.9d 1987–93 1.4d 1993–99 0.3
White, both sexes All ages 1973–92 0.4d 1992–99 0.9d
 20 1973–99 2.8d
20–49 1973–79 1.7d 1979–91 1.2d 1991–99 2.0d
 50 1973–78 1.9d 1978–91 1.3d 1991–99 2.0d
50–64 1973–88 0.2d 1988–94 1.2d 1994–99 2.2d
65–74 1973–86 0.9d 1986–94 0.2d 1994–99 1.0d
75 1973–93 0.9d 1993–99 0.2
White, males All ages 1973–80 0.8d 1980–92 0.2d 1992–99 1.4d
 20 1973–99 2.9d
20–49 1973–99 1.4d
 50 1973–99 1.5d
50–64 1973–88 0.1d 1988–94 1.4d 1994–99 2.4d
65–74 1973–79 0.9d 1979–90 0.2d 1990–94 0.5 1994–99 1.2d
75 1973–79 1.5d 1979–92 0.8d 1992–99 1.1d
White, females All ages 1973–93 0.5d 1993–99 0.8d
 20 1973–99 2.6d
20–49 1973–79 1.9d 1979–90 1.0d 1990–99 2.1d
 50 1973–79 2.0d 1979–90 1.0d 1990–99 2.1d
50–64 1973–87 0.3d 1987–95 0.9d 1995–99 2.4d
65–74 1973–75 0.1 1975–86 1.5d 1986–94 0.6d 1994–99 0.7d
75 1973–87 0.8d 1987–93 1.4d 1993–99 0.3
Black, both sexes All ages 1973–84 1.3d 1984–92 0.6d 1992–99 1.2d
 20 1973–99 2.2d
20–49 1973–92 1.0d 1992–99 2.5d
 50 1973–92 1.0d 1992–99 2.5d
50–64 1973–84 0.8d 1984–90 0.4 1990–99 1.9d
65–74 1973–75 0.6 1975–89 1.5d 1989–95 0.1 1995–99 2.6d
75 1973–80 2.8d 1980–91 1.8d 1991–99 0.1
Black, males All ages 1973–82 1.9d 1982–90 1.0d 1990–93 0.5 1993–99 2.1d
 20 1973–99 2.4d
20–49 1973–79 0.2 1979–91 1.2d 1991–99 3.0d
 50 1973–79 0.0 1979–91 1.3d 1991–99 3.0d
50–64 1973–84 1.0d 1984–87 1.5 1987–90 0.5 1990–99 2.3d
65–74 1973–83 2.0d 1983–89 1.3d 1989–95 0.9d 1995–99 3.9d
75 1973–80 3.2d 1980–91 2.3d 1991–99 0.9d
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TABLE 2
(continued)
Mortality
Line segment 1 Line segment 2 Line segment 3 Line segment 4
Year APCc Year APCc Year APCc Year APCc
Black, females All ages 1973–75 0.8 1975–91 1.0d 1991–99 0.4d
 20 1973–99 2.0d
20–49 1973–76 4.2d 1976–92 0.7d 1992–99 1.9d
 50 1973–76 4.3d 1976–92 0.8d 1992–99 1.9d
50–64 1973–87 0.7d 1987–99 1.2d
65–74 1973–76 2.0 1976–93 1.6d 1993–99 0.7d
75 1973–82 2.8d 1982–99 1.4d
Lung and bronchus All races, both sexes All ages 1973–80 3.0d 1980–90 1.8d 1990–97 0.2 1997–99 1.9d
 50 1973–80 0.4d 1980–91 2.4d 1991–94 4.6d 1994–99 2.5d
50–64 1973–79 2.6d 1979–88 1.2d 1988–93 1.3d 1993–99 3.2d
65–74 1973–82 3.4d 1982–91 2.0d 1991–97 0.2 1997–99 2.0d
75 1973–80 4.2d 1980–91 3.4d 1991–97 1.5d 1997–99 0.2
All races, males All ages 1973–80 2.2d 1980–90 0.7d 1990–97 1.5d 1997–99 2.8d
 50 1973–80 1.6d 1980–90 3.0d 1990–99 4.0d
50–64 1973–78 1.6d 1978–88 0.2 1988–93 2.2d 1993–99 3.9d
65–74 1973–80 2.2d 1980–90 0.6d 1990–97 0.8d 1997–99 3.0d
75 1973–77 4.6d 1977–83 3.1d 1983–91 1.6d 1991–99 0.8d
All races, females All ages 1973–82 6.1d 1982–90 4.1d 1990–95 1.9d 1995–99 0.2
 50 1973–78 3.0d 1978–87 0.9d 1987–99 2.3d
50–64 1973–82 5.7d 1982–90 2.5d 1990–99 1.4d
65–74 1973–83 8.9d 1983–92 4.8d 1992–99 1.1d
75 1973–92 6.8d 1992–97 3.7d 1997–99 1.3
White, both sexes All ages 1973–80 2.9d 1980–90 1.8d 1990–97 0.1 1997–99 1.9d
 50 1973–81 0.6d 1981–91 2.5d 1991–94 4.7d 1994–99 2.5d
50–64 1973–78 2.8d 1978–88 1.3d 1988–93 1.1d 1993–99 3.1d
65–74 1973–82 3.3d 1982–91 1.9d 1991–97 0.4d 1997–99 1.8d
75 1973–77 4.8d 1977–91 3.4d 1991–97 1.5d 1997–99 0.2
White, males All ages 1973–80 2.1d 1980–90 0.6d 1990–97 1.4d 1997–99 2.7d
 50 1973–81 1.9d 1981–91 3.1d 1991–94 5.2d 1994–99 3.0d
50–64 1973–78 1.4d 1978–88 0.2 1988–93 2.1d 1993–99 3.9d
65–74 1973–80 1.9d 1980–90 0.5d 1990–97 0.7d 1997–99 2.8d
75 1973–77 4.6d 1977–83 3.0d 1983–91 1.4d 1991–99 0.8d
White, females All ages 1973–82 6.2d 1982–90 4.2d 1990–95 2.1d 1995–99 0.2
 50 1973–78 3.2d 1978–87 0.7d 1987–99 2.5d
50–64 1973–82 5.6d 1982–90 2.5d 1990–96 0.7 1996–99 3.1d
65–74 1973–83 9.1d 1983–92 4.7d 1992–99 1.2d
75 1973–92 6.9d 1992–97 3.8d 1997–99 1.0
Black, both sexes All ages 1973–81 3.4d 1981–90 1.9d 1990–99 0.9d
 50 1973–77 0.9 1977–91 1.9d 1991–99 3.7d
50–64 1973–82 2.9d 1982–90 0.2 1990–99 3.0d
65–74 1973–88 4.0d 1988–95 0.7 1995–99 2.6d
75 1973–88 4.9d 1988–99 2.0d
Black, males Al ages 1973–81 3.1d 1981–89 1.6d 1989–93 0.8 1993–99 2.6d
 50 1973–77 0.6 1977–91 2.4d 1991–99 5.0d
50–64 1973–82 1.9d 1982–90 0.4 1990–99 3.4d
65–74 1973–82 4.3d 1982–89 2.3d 1989–95 1.2 1995–99 4.0d
75 1973–88 4.9d 1988–94 1.2d 1994–99 0.9
Black, females All ages 1973–82 6.2d 1982–91 3.8d 1991–99 1.2d
 50 1973–99 0.9d
50–64 1973–81 8.2d 1981–90 2.3d 1990–99 2.0d
65–74 1973–92 7.1d 1992–99 1.1
75 1973–91 6.7d 1991–99 4.6d
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(continued)
Mortality
Line segment 1 Line segment 2 Line segment 3 Line segment 4
Year APCc Year APCc Year APCc Year APCc
Colon and rectum All races, both sexes All ages 1973–78 0.0 1978–85 0.8d 1985–99 1.7d
 50 1973–91 2.0d 1991–99 0.4
50–64 1973–85 0.9d 1985–99 1.9d
65–74 1973–84 0.5d 1984–99 2.0d
75 1973–80 0.4 1980–90 1.1d 1990–99 1.8d
All races, males Al ages 1973–79 0.5 1979–87 0.6d 1987–99 2.0d
 50 1973–99 1.4d
50–64 1973–85 0.2 1985–99 1.6d
65–74 1973–85 0.1 1985–99 2.0d
75 1973–80 0.9d 1980–90 0.8d 1990–99 2.4d
All races, females All ages 1973–80 0.5d 1980–99 1.7d
 50 1973–89 2.7d 1989–99 0.4
50–64 1973–85 1.6d 1985–99 2.2d
65–74 1973–84 1.1d 1984–99 2.1d
75 1973–81 0.1 1981–99 1.4d
White, both sexes All ages 1973–78 0.1 1978–84 0.8d 1984–99 1.8d
 50 1973–93 2.2d 1993–99 0.2
50–64 1973–85 1.0d 1985–99 2.1d
65–74 1973–84 0.6d 1984–99 2.1d
75 1973–78 0.5 1978–84 0.6 1984–99 1.7d
White, males All ages 1973–79 0.4 1979–87 0.8d 1987–99 2.1d
 50 1973–99 1.6d
50–64 1973–85 0.3d 1985–99 1.9d
65–74 1973–78 0.6 1978–85 0.6d 1985–99 2.1d
75 1973–80 0.7d 1980–90 1.0d 1990–99 2.5d
White, females All ages 1973–80 0.6d 1980–99 1.8d
 50 1973–89 3.1d 1989–99 0.7d
50–64 1973–84 1.7d 1984–99 2.4d
65–74 1973–84 1.2d 1984–99 2.3d
75 1973–81 0.1 1981–99 1.6d
Black, both sexes All ages 1973–85 1.1d 1985–99 0.3d
 50 1973–99 0.5d
50–64 1973–99 0.0
65–74 1973–89 0.5d 1989–99 0.9d
75 1973–85 2.0d 1985–99 0.1
Black, males All ages 1973–90 1.3d 1990–99 1.0d
 50 1973–99 0.3
50–64 1973–99 0.7d
65–74 1973–85 1.5d 1985–97 0.1 1997–99 6.0
75 1973–90 1.9d 1990–99 1.4d
Black, females All ages 1973–85 0.7d 1985–99 0.5d
 50 1973–99 0.7d
50–64 1973–99 0.8d
65–74 1973–99 0.4d
75 1973–85 1.8d 1985–99 0.1
Female breast All races All ages 1973–79 0.3 1979–89 0.6d 1989–95 1.4d 1995–99 3.2d
 50 1973–80 1.5d 1980–89 0.1 1989–97 2.7d 1997–99 7.4d
50–64 1973–89 0.1 1989–99 2.7d
65–74 1973–75 1.7 1975–89 1.1d 1989–94 1.2 1994–99 3.3d
75 1973–93 1.0d 1993–99 1.3d
White All ages 1973–79 0.3 1979–89 0.5d 1989–95 1.6d 1995–99 3.5d
 50 1973–79 1.7d 1979–90 0.4 1990–97 3.4d 1997–99 8.2d
50–64 1973–89 0.2d 1989–99 3.0d
65–74 1973–89 0.9d 1989–94 1.3 1994–99 3.5d
75 1973–79 0.0 1979–93 1.1d 1993–99 1.6d
(continued)
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cancer deaths in each age group. Prostate carcinoma
was the cause of 20% of the cancer deaths in men aged
75 years and older. In persons aged 75 years and older,
most cancer death rates including lung, colorectal,
prostate, and breast, were higher than rates for per-
sons aged 65-74 years.
Cancer Survival and Prevalence
Once diagnosed with cancer, prognosis (or survival) is
more influenced by the type of cancer and extent of
the disease than a person’s age (Fig. 4). Thus, in con-
trast to the steady increase in cancer incidence or
death rates as a person ages, age does not appreciably
affect relative survival rates for many sites. As an in-
dicator of prognosis, men diagnosed with prostate
cancer had a five year relative survival of at least 90%,
and women diagnosed with breast cancer had a five
year relative survival of 84% or higher. For men and
women diagnosed with colorectal cancer, the five year
relative survival was about 60%. For cancer of the lung,
all of the rates were low (less than 20%), but younger
patients had better survival (19%) than older patients
(9%). However, observed five year survival rates show
greater differences by age, with consistently lower
rates among older persons, particularly persons aged
75 years and older. These lower observed survival rates
reflect death due to other causes as well as to cancer
and the presence of comorbidities.
The estimated number of cancer survivors in the
United States is 8.9 million, based on data from the
SEER Program. About 60% are 65 years and older, and
32% are 75 years and older. These estimates reflect
age-specific cancer incidence rates and survival within
the total population.
Impact of Age on Projected Cancer Cases 2000 to 2050
Because of complex factors that affect changes in can-
cer incidence, it is difficult to anticipate what the rates
will be over the next 50 years. However, if current
cancer incidence rates were applied to the U.S. Census
Bureau population projections for the next five de-
cades (Fig. 5), due to population growth and aging, the
number of cancer patients is expected to double from
1.3 million to 2.6 million persons between 2000 and
TABLE 2
(continued)
Mortality
Line segment 1 Line segment 2 Line segment 3 Line segment 4
Year APCc Year APCc Year APCc Year APCc
Black All ages 1973–93 1.3d 1993–99 1.2d
 50 1973–76 5.4 1976–87 2.0d 1987–99 1.4d
50–64 1973–90 1.2d 1990–99 1.0d
65–74 1973–75 7.8 1975–94 1.9d 1994–99 2.2
75 1973–99 1.9d
Prostate All races All ages 1973–87 0.9d 1987–91 3.0d 1991–94 0.7 1994–99 4.3d
 50 1973–99 0.5
50–64 1973–87 0.3 1987–90 4.3 1990–99 3.8d
65–74 1973–82 0.2 1982–92 1.4d 1992–99 4.7d
75 1973–87 1.1d 1987–93 2.7d 1993–99 3.8d
White All ages 1973–87 0.8d 1987–91 3.1d 1991–94 0.9 1994–99 4.4d
 50 1973–99 0.3
50–64 1973–87 0.4d 1987–90 4.3 1990–99 4.4d
65–74 1973–84 0.3d 1984–91 1.9d 1991–96 3.7d 1996–99 6.4d
75 1973–87 0.8d 1987–91 3.4d 1991–94 0.0 1994–99 4.1d
Black All ages 1973–93 2.2d 1993–99 2.5d
 50 1973–99 1.1d
50–64 1973–87 0.0 1987–90 4.0 1990–99 2.1d
65–74 1973–94 1.2d 1994–99 5.5d
75 1973–93 2.7d 1993–99 1.9d
a Joinpoint analysis of trends allowed for up to three joinpoints based on rates per 100,000 that were age-adjusted to the 2000 U.S. standard population.
b Death data are from the National Vital Statistics System of the National Center for Health Statistics; the data cover the entire U.S. population.
c The APC is the Annual Percent Change based on rates age-adjusted to the 2000 U.S. standard population using the joinpoint regression program.
d The APC is statistically significantly different from zero (two-sided P  .05).
e Joinpoint results are not shown if less than 10 cases in any year.
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TABLE 3
Average Annual Cancer Incidence Ratesa and Percent Site Distribution for the 10 Most Frequent Cancers by Sex and Age, SEER and NPCR
Areas,b United States, 1995–1999
Male and female
rate
Male
rate
Female
rate
Male and female
percent
Male
percent
Female
percent
All ages
All sites 475.1 559.5 420.1 100.0 100.0 100.0
Breast 72.7 1.3 131.9 15.2 0.2 30.7
Prostate 68.9 160.6 c 14.5 28.6 c
Lung and bronchus 68.5 91.5 52.0 14.4 16.3 12.5
Colon and rectum 56.9 67.4 49.0 11.9 11.7 12.2
Urinary bladder 21.6 38.0 9.9 4.5 6.6 2.5
Non-Hodgkin lymphoma 19.1 23.0 15.9 4.0 4.2 3.8
Melanomas of the skin 14.2 17.9 11.5 3.0 3.3 2.7
Corpus and uterus, NOS 13.9 c 25.2 2.9 c 5.9
Leukemias 12.0 15.6 9.3 2.5 2.8 2.3
Kidney and renal pelvis 11.6 15.9 8.2 2.4 2.9 1.9
Other 115.7 128.3 107.2 24.5 23.4 25.6
Ages  20 years
All sites 16.0 16.7 15.1 100.0 100.0 100.0
Leukemias 4.1 4.6 3.6 26.0 27.7 24.1
Brain and other nervous system 2.8 3.0 2.6 17.6 17.8 17.4
Hodgkin lymphoma 1.3 1.3 1.3 7.8 7.5 8.1
Non-Hodgkin lymphoma 1.1 1.4 0.7 6.7 8.5 4.5
Soft tissue including heart 0.9 0.9 0.9 5.7 5.5 6.0
Bones and joints 0.9 1.0 0.8 5.6 5.9 5.4
Kidney and renal pelvis 0.7 0.6 0.8 4.4 3.6 5.2
Other endocrine including thymus 0.5 0.6 0.4 3.3 3.8 2.7
Thyroid 0.5 0.2 0.9 3.2 1.1 5.8
Testis 0.5 0.9 c 3.0 5.6 c
Other 2.7 2.2 3.1 16.6 13.0 20.8
Ages 20–49
All sites 145.5 111.8 178.5 100.0 100.0 100.0
Breast 35.9 0.3 70.6 24.4 0.2 39.2
Melanomas of the skin 10.6 10.0 11.2 7.4 9.0 6.4
Colon and rectum 9.1 9.7 8.5 6.2 8.5 4.8
Lung and bronchus 8.9 9.9 8.0 6.0 8.6 4.4
Non-Hodgkin lymphoma 8.3 10.7 6.0 5.8 9.7 3.4
Thyroid 7.7 3.2 12.2 5.4 2.9 7.0
Cervix 6.5 c 13.0 4.6 c 7.4
Testis 5.1 10.2 c 3.6 9.5 c
Ovary 4.9 c 9.8 3.4 c 5.5
Oral cavity and pharynx 4.4 6.3 2.5 3.0 5.5 1.4
Other 44.1 51.5 36.7 30.3 46.0 20.6
Ages 50–64 years
All sites 864.8 934.2 802.8 100.0 100.0 100.0
Breast 156.7 2.3 299.3 18.0 0.3 37.1
Prostate 134.6 281.8 c 15.7 30.3 c
Lung and bronchus 129.0 157.2 103.2 15.0 16.8 13.0
Colon and rectum 85.4 101.8 70.4 9.9 10.9 8.8
Corpus and uterus, NOS 33.9 c 65.1 3.9 c 8.1
Urinary bladder 32.5 51.7 14.9 3.8 5.5 1.9
Non-Hodgkin lymphoma 31.3 36.5 26.4 3.6 3.9 3.3
Melanomas of the skin 26.2 33.4 19.6 3.0 3.6 2.4
Oral cavity and pharynx 25.3 38.7 12.9 2.9 4.1 1.6
Kidney and renal pelvis 24.2 33.1 15.9 2.8 3.5 2.0
Other 185.7 197.7 175.1 21.4 21.1 21.8
Ages 65–74 years
All sites 2006.6 2604.9 1527.4 100.0 100.0 100.0
Prostate 414.7 931.5 c 20.7 35.8 c
Lung and bronchus 357.0 473.0 264.2 17.8 18.2 17.3
Breast 243.0 5.3 434.1 12.1 0.2 28.4
(continued)
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2050. In addition, the number and proportion of older
persons with cancer are expected to increase dramat-
ically. For example, in 2000 an estimated 389,000 per-
sons aged 75 years and older are expected to be newly
diagnosed with cancer, in contrast to a projection of
nearly 1,102,000 persons in 2050, an increase from
30% to 42% of the cancer population aged 75 years
and older. The number of cancer patients aged 85
years and older is expected to increase by more than
four-fold between 2000 and 2050. Of more immediate
concern, within the next 30 years, the absolute num-
ber of cancers occurring in persons aged 65 years and
older is expected to double.
Race/Ethnic Incidence and Death Rates (White, Black,
API, AI/AN, Hispanic)
Cancer incidence rates from SEER for all sites com-
bined for men in the five racial and ethnic populations
showed that black men had the highest cancer inci-
dence and death rates for each age group, except
persons under age 20 years during 1995-1999 (Tables 5
and 6). White and Hispanic men had the same death
rate in the younger than 20 years age group (Table 6).
White women had the highest cancer incidence rates
for all sites combined for each age group (Table 5),
and black women had the highest cancer death rates
(Table 6). In addition, AI/AN men and women had the
lowest cancer incidence rates for all sites combined
regardless of age (Table 5), while the age-specific can-
cer death rates for AI/AN, API, and Hispanic popula-
tions were lower than for white and black populations
(Table 6).
Black men and women almost always had the
highest colorectal cancer incidence and death rates
during 1995-1999 (Tables 5 and 6). This high ranking
persisted in all age groups for both men and women
for incidence and death rates with one exception:
white men aged 75 years and older had the highest
colorectal cancer incidence rates. Among women, His-
panic women generally had the lowest colorectal cancer
incidence and death rates. Among men, the lowest rates
varied by age among Hispanic, API, and AI/AN men.
Black men had the highest lung cancer incidence
and mortality rates in all age groups during 1995-1999
(Tables 5 and 6). Among women, black women had
higher lung cancer incidence and death rates than
TABLE 3
(continued)
Male and female
rate
Male
rate
Female
rate
Male and female
percent
Male
percent
Female
percent
Colon and rectum 240.6 293.8 198.0 12.0 11.3 13.0
Urinary bladder 100.0 170.8 43.4 5.0 6.5 2.8
Non-Hodgkin lymphoma 68.8 80.0 59.9 3.4 3.1 3.9
Corpus and uterus, NOS 54.6 c 98.5 2.7 c 6.4
Kidney and renal pelvis 48.0 66.9 32.8 2.4 2.6 2.1
Pancreas 47.3 55.2 41.0 2.4 2.1 2.7
Melanomas of the skin 41.2 59.4 26.5 2.1 2.3 1.7
Other 391.4 469.0 329.0 19.5 18.0 21.6
Ages 75 years
All sites 2398.8 3210.2 1931.4 100.0 100.0 100.0
Colon and rectum 400.3 472.5 358.7 16.7 14.5 18.7
Lung and bronchus 359.6 535.6 257.8 15.0 16.9 13.2
Prostate 332.6 899.3 c 13.9 28.3 c
Breast 290.0 8.3 455.6 12.1 0.3 23.5
Urinary bladder 146.5 282.7 69.3 6.1 8.7 3.6
Non-Hodgkin lymphoma 97.3 117.7 85.8 4.1 3.7 4.4
Pancreas 76.7 83.4 72.9 3.2 2.6 3.8
Leukemias 67.9 95.6 52.4 2.8 2.9 2.7
Stomach 58.6 86.2 42.9 2.4 2.6 2.3
Corpus and uterus, NOS 55.9 c 89.4 2.3 c 4.6
Other 513.4 628.9 446.6 21.4 19.5 23.2
a Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population.
b Source is SEER and NPCR areas reported by North American Association of Central Cancer Registries as meeting high data quality standards. The areas cover approximately 55% of the U.S. population: California
(Los Angeles and Greater Bay area), Colorado, Connecticut. Delaware, Georgia (Atlanta area), Hawaii, Idaho, Illinois, Iowa, Kentucky, Louisiana, Michigan (Detroit area), Minnesota, Nebraska, New Jersey, New
Mexico, New York, North Carolina, Pennsylvania, Rhode Island, Utah, Washington (Seattle area), West Virginia, Wisconsin, Wyoming.
c Category not applicable or fewer than 25 cases.
SEER: Surveillance, Epidemiology and End Results Program; NPCR: National Program of Cancer Registries; NOS: not otherwise specified.
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white women until age 64 years; after age 64, white
women had the higher rates. Hispanic men had the
lowest lung cancer incidence and death rates for all
age groups, except AI/AN men, who had the lowest
lung cancer incidence rate among men aged 75 years
and older. Hispanic women had the lowest lung can-
cer death rates in all age groups, but the lowest age-
specific incidence rates among women varied be-
tween Hispanic and AI/AN women.
White women had the highest incidence rates of
breast cancer for all ages combined during 1995-1999;
the lowest age-specific incidence rates occurred in
AI/AN women (Table 5). Age-specific breast cancer
death rates were different. Black women had the high-
est death rates regardless of age and API women had
the lowest age-specific death rates, except for women
under age 50 (Table 6). Regardless of age, black men
had the highest prostate cancer incidence and death
rates during 1995-1999 (Tables 5 and 6). In general,
AI/AN men had the lowest prostate cancer incidence
rates (Table 5), and API men had the lowest death
rates (Table 6).
DISCUSSION
The current report examined recent rates and trends
in cancer incidence and mortality and considered the
impact of aging on the future cancer burden, includ-
ing characteristics of the growing population of cancer
survivors. Progress against cancer can be measured by
the reductions in the rate of cancer deaths at each age,
as well as shifts in detecting cancer at earlier and more
treatable stages of disease at diagnosis. Advances in
cancer control and the application of effective inter-
ventions, as well as improved access to state-of-the-
art cancer care, should lead to further reductions in
cancer death rates.25 However, even with these im-
provements, the aging of the U.S. population alone
will increase the number of persons who are diag-
nosed and treated for cancer and who will survive
longer at increasingly older ages.
FIGURE 3. Age distribution and median age for the incidence of major cancers, Surveillance, Epidemiology and End Results (SEER) Program and the National
Program of Cancer Registries (NPCR) areas reported by the North American Association of Central Cancer Registries (NAACCR), 1995-1999. Percents may not add
to 100 due to rounding. Cancer data from SEER and NPCR areas reported by NAACCR as meeting high data quality standards. The areas cover approximately 55%
of the U.S. population: California (Los Angeles and Greater Bay area), Colorado, Connecticut, Delaware, Georgia (Atlanta area), Hawaii, Idaho, Illinois, Iowa, Kentucky,
Louisiana, Michigan (Detroit area), Minnesota, Nebraska, New Jersey, New Mexico, New York, North Carolina, Pennsylvania, Rhode Island, Utah, Washington (Seattle
area), West Virginia, Wisconsin, and Wyoming.
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TABLE 4
Average Annual Cancer Death Ratesa and Percent Site Distribution for the 10 Most Frequent Cancers by Sex and Age,
United Statesb 1995–1999
Male and female
rate
Male
rate
Female
rate
Male and female
percent
Male
percent
Female
percent
All ages
All malignant cancers 205.9 259.1 171.4 100.0 100.0 100.0
Lung and bronchus 57.7 81.2 41.0 28.2 32.2 23.7
Colon and rectum 21.7 26.3 18.5 10.5 10.0 11.1
Breast 16.4 0.3 28.8 7.9 0.1 16.3
Prostate 12.6 33.9 c 6.1 11.7 c
Pancreas 10.6 12.2 9.3 5.1 4.8 5.5
Non-Hodgkin lymphoma 8.7 10.8 7.2 4.2 4.2 4.3
Leukemias 7.8 10.4 6.0 3.8 4.0 3.5
Ovary 5.1 c 9.0 2.5 c 5.2
Stomach 5.0 7.1 3.5 2.4 2.7 2.1
Brain and other nervous system 4.7 5.7 3.9 2.3 2.4 2.2
Other 55.6 71.2 44.2 26.9 27.8 26.0
 20 years
All malignant cancers 2.9 3.2 2.6 100.0 100.0 100.0
Leukemias 0.9 1.1 0.8 32.1 32.7 31.4
Brain and other nervous system 0.7 0.8 0.6 24.4 23.6 25.4
Other endocrine 0.2 0.3 0.2 8.2 8.4 7.8
Bones and joints 0.2 0.3 0.2 7.8 8.0 7.6
Soft tissue including heart 0.2 0.2 0.2 6.6 6.3 6.9
Non-Hodgkin lymphoma 0.2 0.2 0.1 5.5 6.7 3.8
Kidney and renal pelvis 0.1 0.1 0.1 2.8 2.2 3.6
Liver and intrahepatic bile duct 0.1 0.1 0.1 2.5 2.6 2.4
Hodgkin disease 0.0 0.0 0.0 1.5 1.3 1.8
Colon and rectum 0.0 0.0 0.0 0.8 0.8 0.7
Other 0.3 0.1 0.3 7.8 7.2 8.7
20–49 years
All malignant cancers 35.2 33.7 36.7 100.0 100.0 100.0
Lung and bronchus 6.1 7.2 5.0 17.1 21.1 13.4
Breast 5.6 0.0 11.0 15.8 0.1 29.9
Colon and rectum 2.7 2.9 2.4 7.5 8.6 6.6
Brain and other nervous system 2.1 2.6 1.6 6.0 7.7 4.4
Non-Hodgkin lymphoma 2.0 2.7 1.3 5.8 8.2 3.6
Leukemias 1.9 2.2 1.6 5.5 6.7 4.4
Cervix 1.3 c 2.6 3.8 c 7.1
Melanoma of the skin 1.3 1.6 0.9 3.6 4.7 2.6
Pancreas 1.2 1.5 0.9 3.4 4.5 2.5
Ovary 1.0 c 2.1 2.9 c 5.6
Other 10.0 13.0 7.3 28.6 38.3 19.9
50–64 years
All malignant cancers 304.3 343.1 269.1 100.0 100.0 100.0
Lung and bronchus 98.7 127.1 72.8 32.5 37.1 27.2
Breast 29.7 0.5 56.5 9.7 0.1 20.8
Colon and rectum 26.7 32.3 21.6 8.8 9.4 8.0
Pancreas 15.0 18.4 11.9 4.9 5.4 4.5
Non-Hodgkin lymphoma 11.2 14.1 8.6 3.7 4.1 3.2
Brain and other nervous system 8.9 10.7 7.2 2.9 3.1 2.7
Leukemias 8.5 10.5 6.6 2.8 3.1 2.5
Ovary 8.5 c 16.3 2.8 c 6.0
Esophagus 8.4 14.6 2.8 2.8 4.3 1.0
Kidney and renal pelvis 7.5 10.8 4.5 2.5 3.1 1.7
Other 81.2 104.1 60.3 26.7 30.3 22.4
(continued)
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Age-adjusted cancer incidence rates for all can-
cers combined remained essentially constant during
the most recent reporting period (1995-1999),
whereas death rates decreased during the period
1993 through 1999. The stable pattern of overall
age-adjusted cancer incidence rates in the past five
years is a complex mix of different trends in age-
specific cancer rates, particularly for the more com-
mon cancers. The relatively constant rate includes
continuing increases in cancer incidence rates
among women aged 65-74 years, increases in breast
cancer among women aged 50-64 years, increases in
colorectal cancer for women under age 50 years,
increases in prostate cancer for men under age 65
years, and increases in lung cancer for persons aged
75 years and older. These increases are offset by
declines in lung and colorectal cancer incidence for
men at all but the oldest ages.
In contrast, the death rate for all cancers com-
bined continued to decrease in the entire U.S. popu-
lation through 1999. The decline in cancer death rates
accelerated during the 1990s in most age groups of
men and women, with the notable exception of a
slowing of the increase in lung cancer death rates in
older aged women. The long-term temporal trends in
cancer mortality reflect a combination of birth cohort
effects in exposures as such tobacco use and period
effects from the introduction of screening combined
with more effective treatments for breast and colorec-
tal cancers, as well as improved medical management
for prostate cancers.26 Birth cohort patterns in ciga-
rette smoking have a strong but delayed effect on both
incidence and death rates from cancer, leading to the
progressive increase and later decrease in lung cancer
incidence and mortality rates. Both the uptake of reg-
ular cigarette smoking and reductions in smoking
prevalence occurred earlier in men than in women in
the United States.
Many factors influence the age-adjusted cancer
incidence trends. Routine screening has not only in-
creased in the population, but it also has improved the
prognosis for cancer patients, especially persons diag-
nosed with early stage disease. The widespread intro-
duction of mammography in the 1980s coincided with
TABLE 4
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Male and female
rate
Male
rate
Female
rate
Male and female
percent
Male
percent
Female
percent
65–74 years
All malignant cancers 852.5 1067.1 680.3 100.0 100.0 100.0
Lung and bronchus 294.3 404.4 205.8 34.5 37.9 30.3
Colon and rectum 81.9 102.7 65.2 9.6 9.6 9.6
Breast 53.7 1.1 95.9 6.3 0.1 14.1
Pancreas 44.4 52.1 38.2 5.2 4.9 5.6
Prostate 44.4 100.0 c 5.2 9.3 c
Non-Hodgkin lymphoma 32.9 39.8 27.4 3.9 3.7 4.0
Leukemias 27.6 37.7 19.4 3.2 3.5 2.9
Ovary 20.4 c 36.8 2.4 c 5.4
Esophagus 20.0 35.1 7.8 2.3 3.3 1.2
Liver and intrahepatic bile duct 19.0 27.6 12.1 2.2 2.6 1.8
Other 213.9 266.6 171.7 25.1 25.0 25.2
75 years
All malignant cancers 1454.8 2013.3 1148.3 100.0 100.0 100.0
Lung and bronchus 344.9 534.3 236.3 23.8 27.4 20.2
Colon and rectum 184.9 221.3 164.0 12.7 10.9 14.5
Prostate 143.8 418.0 c 9.9 19.9 c
Breast 98.1 2.7 151.4 6.7 0.1 13.2
Pancreas 80.6 88.7 75.8 5.5 4.4 6.6
Non-Hodgkin lymphoma 65.6 79.8 57.7 4.5 4.0 5.0
Leukemias 59.9 84.1 46.4 4.1 4.2 4.1
Urinary bladder 44.7 81.7 25.0 3.1 3.9 2.2
Stomach 39.2 56.5 29.4 2.7 2.8 2.6
Ovary 33.7 c 53.1 2.3 c 4.6
Other 359.4 446.2 309.2 24.7 22.4 27.0
a Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population.
b Source: Death data are from the National Vital Statistics System of the National Center for Health Statistics; the data cover the entire U.S. population.
c Category not applicable or fewer than 25 cases.
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a sharp increase in breast cancer incidence. Trends in
the diagnosis of breast cancer continue to rise, partic-
ularly early stage disease among women aged 50-64
years (data not shown). Changes in medical manage-
ment (surgery and pathology) of women with breast
cancer may have affected the recent increase in the
trend for node positive disease (data not shown). For
men, the promotion of prostate specific antigen
screening created a sharp increase in prostate cancer
incidence between 1988 and 1992. For men and
women, the modest increase in colorectal screening
may have contributed to the observed increases in
incidence during the 1990s in some age, sex, and race
groups. Future advances in tests for the early detec-
tion of cancers, such as patterns of proteins found in
patients’ blood,27 may alter cancer incidence trends
further. Increases in screening are typically reflected
by period increases in cancer incidence, meaning that
the increase occurs simultaneously across all age
groups receiving the screening.
FIGURE 4. Five-year observed and
relative survival rates by selected site
and age, Surveillance, Epidemiology,
and End Results (SEER) Program, 1990-
1998. Survival rates are expressed as
percents for 1990-1998 data, followed
through 1999, and are based on SEER
registries covering 10% of the U.S. pop-
ulation: metropolitan areas of San Fran-
cisco-Oakland, Detroit, Atlanta, and Se-
attle-Puget Sound; and states of
Connecticut, Hawaii, Iowa, Utah, and
New Mexico.
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Cancer occurs predominantly in older persons,
with a median age at diagnosis of 68 years. The num-
ber of cancer survivors is growing, as is the proportion
of individuals aged 65 years and older. This represents
an important group of persons with unique needs and
risks for cancer.28 However, the proportion of patients
in this age category is under-represented in clinical
trials.29,30 Clinical trials are the most valued resource
for identifying promising new interventions, and for
evaluating the effectiveness of new interventions com-
pared to standard ones. Since March 1998, more than
177,000 patients have enrolled in NCI-sponsored
Phase III trials, and one-quarter were aged 65 or older
at the time of study entry. Categorized by the most
common tumors (e.g., breast, prostate, colorectal, or
lung), the percentages enrolled were 17%, 72%, 45%,
and 43%, respectively. Among 52,000 patients enrolled
in NCI-sponsored earlier phase (e.g., Phases I, I/II, and
II) clinical trials since 1998, 28% were aged 65 years or
older. Although efforts are underway to implement
and evaluate several key pilot studies designed to im-
prove access to the nationwide clinical trials system,
specific strategies are needed to increase the propor-
tion of older patients on appropriately designed clin-
ical trials.
Older age patients with cancer present many chal-
lenges to practicing health care providers. There is a
limited knowledge base of drug-drug interactions with
new therapies in older age patients. Older patients are
more likely to be on a variety of medicines that inter-
act with their anti-tumor therapy and thus are at
heightened risk for drug-drug interactions and over-
lapping toxicities. In addition, underlying physiologic
changes in organ function, in the absence of poly-
pharmacy, may place older patients at increased risk
for toxicities and result in decreased tolerance for
standard regimens.31–33 Co-morbid conditions, such
as vascular disease, may exist, and there may be un-
known hazards in exposing a patient with pre-existing
risks for a stroke or coronary artery disease to anti-
angiogenesis agents.34 –36
Each of the annual reports has described impor-
tant progress against cancer.1– 4 These advances re-
sult from breakthroughs in treatment and early de-
tection modalities and understanding the biology
and behavioral advances to encourage adherence to
recommended preventive practices and early detec-
tion regimens to avoid or minimize cancer risks.
Despite the progress, the future aging of the popu-
lation will dramatically increase the number of can-
cers and the age of most cancer patients. Barring
major breakthroughs in cancer prevention, pro-
jected U.S. population growth and aging are ex-
pected to contribute to a progressive and substan-
FIGURE 5. Projected number of cancer cases for 2000 through 2050 based on projected census population estimates and age-specific cancer incidence rates,
Surveillance, Epidemiology and End Results (SEER) Program and the National Program of Cancer Registries (NPCR) areas reported by the North American Association
of Central Cancer Registries (NAACCR), 1995-1999. Projections based on current (1995-1999) age-specific incidence rates applied to projected census populations
for 2000 to 2050. Population data from census populations 2000 - 2050. Cancer data from SEER and NPCR areas reported by NAACCR as meeting high data quality
standards. The areas cover approximately 55% of the U.S. population: California (Los Angeles and Greater Bay area), Colorado, Connecticut, Delaware, Georgia
(Atlanta area), Hawaii, Idaho, Illinois, Iowa, Kentucky, Louisiana, Michigan (Detroit area), Minnesota, Nebraska, New Jersey, New Mexico, New York, North Carolina,
Pennsylvania, Rhode Island, Utah, Washington (Seattle area), West Virginia, Wisconsin, Wyoming.
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tial increase in the cancer burden, doubling the total
number of persons diagnosed with cancer within
the next half century as well as the number of cancer
patients aged 75 years and older. Thus, the number
of persons who require cancer treatment and re-
quire it at older ages also will increase, placing a
growing demand for more supportive, palliative,
and general medical services.37 The overall costs for
cancer are estimated to be $156.7 billion in the year
2001 (Dr. Martin Brown, NCI, personal communica-
tions), and will continue to increase.38
Even as all Americans are aging, the nation is
growing more diverse. In the 2000 U.S. Census,7 the
Hispanic population in the United States was as large
as the black population, having nearly doubled during
the 1990s. The Census category for Asian/Pacific Is-
landers (API) also reflects growing numbers and
makes up a higher proportion of the U.S. population.
Within the API category, the composition of recent
immigrants (by country of origin) is different from
second generation APIs. Since cancer incidence and
death rates vary among the race/ethnic groups, these
changes will have implications not only for the cancer
burden as these populations grow and age, but also on
a greater need for culturally appropriate prevention,
early detection, and treatment programs.
Higher incidence and/or death rates among se-
lected racial and ethnic populations show that not all
populations have benefited equally from cancer pre-
vention and treatment control efforts.1– 4 Even though
rates for these cancers may be relatively low among
some populations, greater efforts are needed to over-
come negative health disparities. This will require at-
tention to education, costs, access, and cultural ap-
propriateness.
Limitations
Findings in the current report may have method-
ologic, substantive, and interpretive limitations. Some
of the statistically significant findings in analyses that
TABLE 5
Average Annual Cancer Incidence Ratesa by Age, Sex, and Race/Ethnicity,b SEER,c 1995–1999
Male Female
White
rate
Black
rate
AI/AN
rate
API
rate
Hispanic
rate
White
rate
Black
rate
AI/AN
rate
API
rate
Hispanic
rate
All sites All ages 546.1 674.5 268.2 401.6 378.2 All sites 427.0 405.3 228.1 310.6 288.2
 20 years 17.4 13.0 9.4 15.5 15.7 16.2 11.4 7.7 13.3 14.7
20–49 years 111.5 133.6 56.1 76.5 75.8 179.2 162.6 97.8 154.1 137.1
 50 years 74.2 85.8 37.6 52.3 52.0 114.6 102.6 62.1 98.3 88.6
50–64 years 902.7 1372.3 485.0 560.6 601.8 830.5 815.6 486.8 598.1 549.1
65–74 years 2508.3 3049.5 1167.0 1844.9 1814.8 1538.8 1457.3 776.0 987.5 969.9
75 years 3172.2 3401.0 1511.2 2615.8 2161.6 1953.7 1863.3 976.2 1401.0 1286.9
Colon/rectum All ages 63.1 69.3 41.3 58.9 43.8 Colon/rectum 45.7 55.6 32.6 39.2 29.4
 50 years 5.1 7.1 4.6 6.3 4.1 4.5 6.5 4.8 5.5 3.7
50–64 years 92.6 128.8 86.2 92.4 73.2 64.5 93.7 64.3 62.7 47.6
65–74 years 269.9 279.1 171.9 251.1 201.9 182.7 228.0 140.4 145.6 114.2
75 years 458.6 438.3 225.9 397.4 274.4 343.6 360.4 169.1 268.1 199.7
Lung All ages 79.8 120.6 50.0 63.1 42.0 Lung 51.4 53.1 22.9 28.6 22.2
 50 years 4.3 11.3 4.3 3.9 2.0 3.9 6.2 d 2.8 1.7
50–64 years 129.5 251.0 93.4 91.7 60.3 98.4 115.7 52.9 44.4 36.1
65–74 years 411.3 566.6 247.9 329.1 215.4 266.9 259.4 80.7 125.9 108.9
75 years 498.9 618.7 274.0 411.3 286.1 268.9 235.2 139.6 191.7 137.5
Prostate All ages 158.7 257.3 56.4 100.9 120.5 Breast 139.0 121.5 59.7 97.9 83.5
 50 years 3.3 8.8 d 1.2 1.7 42.8 42.2 20.9 39.1 30.5
50–64 years 286.5 546.7 86.7 108.6 187.7 326.1 286.4 165.7 244.6 196.1
65–74 years 916.7 1395.3 277.1 584.7 746.2 458.6 359.0 159.2 274.3 253.4
75 years 875.0 1272.0 409.1 748.1 692.9 477.9 403.5 153.4 245.8 253.6
a Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population.
b Rates other than for whites and blacks should be interpreted with caution because of possible misreporting and misclassification of race/ethnicity; see text for discussion. Hispanic is not mutually exclusive from
whites, blacks, American Indians/Alaska Natives, and Asian/Pacific Islanders.
c Source: Incidence data for 1995–1999 are based on SEER registries covering 14% of the U.S. population: metropolitan areas of San Francisco-Oakland, Detroit, Atlanta, Seattle-Puget Sound, Los Angeles, San
Jose-Monterey; and states of Connecticut, Hawaii, Iowa, Utah, and New Mexico; and Native Americans residing in Alaska. Hispanic rates exclude Detroit and Hawaii.
d Category not applicable or fewer than 25 cases.
SEER: Surveillance, Epidemiology and End Results Program; AI/AN: American Indian/Alaska Native; API: Asian Pacific Islander.
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test multiple comparisons may be due to chance
alone. The analyses in this report examined age-spe-
cific trends among combinations of age groups ( 20
years, 20-49 years, 50 years, 50-64 years, 65-74 years,
and 75 years and older) plus all ages, with race (all,
black, and white), gender (all, women, and men), and
the four major types of cancer. With the large number
of tests, the report could include results that are sta-
tistically spurious.
The impact of shifting from the 1970 standard
population to the 2000 standard population has im-
portant consequences on the levels and trends of can-
cer rates. For all sites combined and for most common
cancer sites, such as colorectal and prostate cancers,
the 2000 standard increased cancer incidence and
death rates by 20% to 50% compared to the 1970
standard, due to an increased representation of the
older age groups with higher cancer rates. In contrast,
the change in population standard attenuates the con-
tinued decline in age-adjusted cancer death rates be-
cause of a reduced weighting of the younger age
groups in which death rates have declined the most.
The change to the year 2000 standard conforms to a
new federal policy for reporting disease rates.
In addition, use of ICD-10, the new classification
for coding cause of death beginning in 1999, may
impact cancer death rates. Differences will occur for
some specific sites. If trends in site-specific death
rates change by an amount that is similar to compa-
rability ratios,18 it is most likely due to the change in
coding. Changes in death rates are still interpretable,
despite the changes in the coding and classification
system between 1998 and 1999.
Limitations in the trend statistics also must be
considered. Results of the joinpoint analysis (JPA) are
not comparable to last year’s annual report4 because a
different population standard for age-adjustment was
used this year, and this change as well as the addition
of the 1999 data point may have altered the joinpoints
and the direction or magnitude of the APC values. The
JPA complicates comparisons across different groups
that have different joinpoints and years of inflection.
Further, the JPA often shows fewer significant changes
in trends for population groups based on small num-
bers of cases or deaths (e.g., the black population or
younger age groups) than for groups based on larger
numbers (e.g., the white population or older age
groups). However, the JPA is a flexible and accurate
approach in identifying the years in which significant
changes in trends occurred.
Although the NAACCR combined rate covers
nearly 55% of the U.S. population, it may not reflect
the United States as a whole. Variability in cancer
incidence rates may arise from differences in socio-
demographic population characteristics (e.g., race and
ethnicity, geography), health behavior (e.g., tobacco
use, diet, physical activity), screening utilization, ex-
posure to cancer causing agents, and/or completeness
and timeliness of cancer reporting.
Finally, assessment of long-term cancer trends is
limited to only white and black populations. Annual
population counts at the county level prior to 1990 for
other populations are not available. Further, cancer
incidence and death rates for some racial and ethnic
populations may be limited by problems in ascertain-
ing race and by misreporting race and ethnicity on the
basic records (medical records, death certificates, and
census reports) from which information is collected
on cancer incidence, deaths, and the population at
risk.39 – 42 Recent studies suggest that reporting race for
the white and black population is generally reliable,
but biases are more serious for some smaller popula-
tions, particularly American Indians.40,42
Strategies for the Future
The population-based data in the current report un-
derscore a critical need for an expanded and orga-
nized focus on cancer control efforts to serve an aging
population and reduce the burden of cancer in the
elderly. The impact of future changes in our nation’s
age structure must be addressed from a multitude of
perspectives, including prevention and early detec-
tion, social support, treatment and medical care, re-
search, and surveillance. Issues of disparity, access,
economics, and quality of life cross-cut all these per-
spectives.
Prevention and early detection
Medical and scientific agreement is needed about rec-
ommendations for screening and early detection of
cancer in persons of all ages, specifically recommen-
dations on the appropriate age to begin screening and
whether recommendations need to be modified for
older age groups. The majority of evidence about
screening will come from individuals of all ages, and
recommendations about whether to modify recom-
mendations in older individuals will have to come
from analyzing subsets of older individuals in these
trials. In addition, other methods, including modeling,
could be used. Such approaches should consider the
substantial decreases that have occurred in the death
rates from breast, prostate, and colorectal cancers.
Screening for colorectal cancer, in particular, must be
increased in all adults aged 50 years and older.43 Pop-
ulation-based data show the need to expand and or-
ganize cancer control efforts for an aging population
and to integrate issues of aging in cancer intervention
research. It is not enough to develop recommenda-
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tions; they must be promoted to both patients and
their health providers to make a population differ-
ence.44 To date, there has been little focused attention
on cancers in older people.28
Social support
The interaction of aging, cancer, and the detrimental
pathology of aging, like the presence of concomitant
diseases, functional limitations, and patient frailty,
has had only sporadic research attention. Systematic
study is needed to ascertain psychologic and social
support resources used by older persons to cope with
the effects of cancer and its treatment, issues of quality
of life and survivorship, and the relevance of access to
care for older patients, their families, and physicians.45,46
Increasingly in the future, families and friends will as-
sume more caregiving responsibilities for which they
are untrained and unaccustomed.47– 49 Also, as care
givers are likely to be older persons, they often have
their own health problems that limit the support they
can provide to others. The situation can be further
exacerbated by reduced income, economic stress, lim-
ited or diminishing social support networks, loss of
loved ones, and changing living arrangements.50 The
relation of these social factors to treatment, survival,
and quality of life of older cancer patients must be
better understood.
Treatment
The special considerations needed in treating cancer
in older persons because of their concomitant ill-
nesses and physical limitations are understudied. Rel-
evant short-term and long-term medical effects in-
clude anti-tumor drug alterations due to age and
aging, dosage, administration, and special monitoring
needs, late life recurrence of cancer, and a possibility
of second primary tumors. Advancing age is associ-
ated with age-related conditions among which the
most prominent life-threatening ones are heart dis-
ease, chronic obstructive pulmonary disease, hyper-
TABLE 6
Average Annual Cancer Death Ratesa by Age, Sex, and Race/Ethnicity,b United States,c 1995–1999
Male Female
White
rate
Black
rate
AI/AN
rate
API
rate
Hispanic
rate
White
rate
Black
rate
AI/AN
rate
API
rate
Hispanic
rate
All sites All ages 253.0 359.2 156.0 157.1 160.7 All sites 169.8 203.5 112.0 103.6 104.2
 20 years 3.3 3.2 2.4 3.0 3.3 2.5 2.8 1.9 2.3 2.8
20–49 years 31.6 53.5 21.2 24.6 22.3 34.9 52.9 27.3 25.3 26.3
 50 years 20.4 33.6 13.7 16.0 14.8 22.1 33.1 17.2 16.2 17.0
50–64 years 326.6 559.5 234.3 190.3 199.7 264.8 342.6 194.2 153.3 158.1
65–74 years 1046.5 1440.1 710.7 625.8 662.9 678.8 793.2 473.2 365.5 394.9
75 years 1991.0 2582.6 1060.5 1254.0 1264.4 1148.6 1257.0 649.3 740.6 697.9
Colon/rectum All ages 25.8 34.4 15.8 15.9 16.6 Colon/rectum 18.0 25.4 11.7 11.3 10.3
 50 years 1.6 3.0 1.3 1.4 1.2 1.3 2.4 1.3 1.3 1.0
50–64 years 31.0 50.6 24.2 18.9 21.9 20.4 33.4 18.1 13.2 13.2
65–74 years 101.1 134.6 65.6 62.1 68.8 62.9 95.0 42.1 40.7 36.9
75 years 220.8 261.1 114.0 132.1 130.5 162.1 204.2 87.8 94.7 85.9
Lung All ages 79.7 109.1 50.4 41.1 37.3 Lung 41.7 40.2 25.3 19.7 13.8
 50 years 4.0 8.5 2.3 2.1 1.6 2.9 4.2 1.6 1.6 0.8
50–64 years 121.7 208.0 86.8 47.8 46.5 74.3 77.6 46.3 25.2 18.4
65–74 years 400.3 513.6 272.0 203.5 178.3 210.6 198.9 134.6 82.6 62.1
75 533.2 626.7 294.2 314.3 288.4 240.9 206.3 138.4 154.7 104.8
Prostate All ages 31.2 72.8 17.5 14.3 21.6 Breast 28.2 37.1 15.0 13.0 17.2
 50 years 0.1 0.3 d d 0.1 6.1 11.2 3.9 4.0 4.8
50–64 years 11.1 36.4 10.2 3.6 8.8 55.0 77.6 32.8 31.7 36.9
65–74 years 88.8 245.6 56.2 34.2 71.7 96.2 112.1 54.3 36.7 53.4
75 years 391.0 842.5 201.9 190.7 256.2 152.3 165.4 61.8 48.1 77.9
a Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population.
b Rates other than for whites and blacks should be interpreted with caution because of possible misreporting and misclassification of race/ethnicity; see text for discussion. Hispanic is not mutually exclusive from
whites, blacks, American Indians/Alaska Natives, and Asian/Pacific Islanders.
c Source: Death data are from the National Vital Statistics System of the National Center for Health Statistics; the data cover the entire U.S. population. Hispanic rates excluded Oklahoma, New York, Connecticut,
and New Hampshire.
d Category not applicable or fewer than 25 cases.
AI/AN: American Indian/Alaska Native; API: Asian Pacific Islander.
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tension, and diabetes. The comorbidity burden of
newly diagnosed cancer patients and coordination of
treatment for these pre-existing problems with cancer
treatment also have had limited attention in clinical
research.35,36,51–53 The responses of older patients to
cancer treatment in the presence of the normal pro-
cesses of aging (e.g., changes in body structure, com-
position, and function) and the pathologic processes
of aging (e.g., comorbid conditions) are not well
known.54 –57 Age alone is not a reason to modify the
standard of care for persons diagnosed with cancer;
cancer survival is less a function of age than of general
health status or the presence of other diseases.54,58
Strategies may include considering placing equal
emphasis on treatment of symptoms (e.g., secondary
to either the treatment or the underlying tumor) and a
greater focus on integrating palliative care issues. Im-
plementation requires integrating new curricula, edu-
cation and training in geriatrics, and geriatric oncol-
ogy, perhaps through partnering with professional
societies28 such as the American Society of Clinical
Oncology, the American Academy of Family Physi-
cians, the American Association for Cancer Education,
and the ACS.
General medical care
With more people vulnerable to cancer, more cancer
patients surviving to older ages, and more older sur-
vivors who are frail or have additional medical prob-
lems, the need and demand for health care provid-
ers,59 particularly nurses in general and for oncology
nurses in particular, will grow. All health provider
specialties, particularly in nursing, are already facing
shortages, the workforce itself is aging, and the short-
ages are expected to worsen.60,61 Other health services,
such as nursing home care, assisted living, and home
health services, are expected to increase to meet not
only health care needs, but also the needs of daily
living as a cancer survivor. Palliation and end-of-life
health and support services will be in greater demand.
Attraction and retention of a workforce in the support-
ive health professions must be incorporated in plan-
ning to meet all the health, medical, social, and phys-
ical needs of a large number of older cancer survivors.
We must also develop the economic infrastructure
that will support such a workforce.
Research and public partnerships
Collaborative approaches to integrate extramural re-
search scientific areas in cancer and aging are improv-
ing,62 particularly within the National Institutes of
Health and with other federal and private agencies.
Partnerships are developing in basic, clinical, and
population sciences to meet the critical need for in-
formation on aging and cancer. Specifically, the NCI
and the National Institute on Aging (NIA) are collab-
orating in the research arena of clinical medicine,
surveillance, and survivorship to address the public
health burden of cancer in older persons.63 Each or-
ganization conducts research in survivorship and col-
laborates with private partners such as the ACS to
provide information to cancer patients and their fam-
ilies, improve access to cancer screening and age-
appropriate therapy for cancer patients, and facilitate
linking cancer patients of all ages with clinical trials.
The NCI is working with its clinical trials cooperative
groups and community oncology program research
base to consider designing and conducting trials that
can evaluate cancer therapy in frail older patients, as
well as patients with comorbid but not necessarily frail
conditions. One of the obstacles to clinical trial access
for the older patient may be the organ function eligi-
bility requirements.64 In addition, the ACS provides
numerous services to cancer patients and their fami-
lies.
Surveillance
The primary resources in the United States for infor-
mation about cancer rates and trends as applied to
information for patients are the National Vital Statis-
tics System, the central cancer registries, surveys of
health practices and risk, and linked data systems.
While the vital records system has had complete cov-
erage for national and state mortality since 1933,65 the
cancer incidence network has been expanded and im-
proved only in recent years11 and is still striving to
meet national coverage. Both systems enable timely,
efficient, and continuous surveillance of cancer occur-
rence. Further, with cancer registries, descriptions of
not only disease burden but also progress are possible;
the program impact of tobacco prevention and cessa-
tion and breast cancer screening can be shown; pa-
tients can be told the probability of surviving specific
cancers; and families can be reassured that age does
not adversely affect survival from cancer. The infor-
mation also helps providers meet the health care vol-
ume and needs of cancer patients. Policy makers can
make appropriate decisions about allocation of scarce
resources to most effectively reduce the cancer bur-
den.
The partnership of the institutions and agencies
represented in this annual report assures that infor-
mation about cancer is continually collected in a stan-
dard and meaningful way and that data are used and
interpreted for their significance to cancer prevention,
early detection, treatment, and survival. This collabo-
ration brings a focus to timely issues, forging a com-
prehensive perspective for setting future directions.
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